Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma

07/23/2021 | 07:17am EDT

KENILWORTH & WOODCLIFF, N.J. - Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. The approval for this population is based on results from the pivotal Phase 3 KEYNOTE-775/Study 309 trial, in which KEYTRUDA plus LENVIMA demonstrated statistically significant improvements in overall survival (OS), reducing the risk of death by 32% (HR=0.68 [95% CI, 0.56-0.84]; p=0.0001), and progression-free survival (PFS), reducing the risk of disease progression or death by 40% (HR=0.60 [95% CI, 0.50-0.72]; p

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
EISAI CO., LTD. 1.61% 8514 End-of-day quote.15.49%
MERCK & CO., INC. 1.40% 73.05 Delayed Quote.-11.93%
All news about MERCK & CO., INC.
09/21MERCK : Thinking about trading options or stock in Draftkings, Merck, ConocoPhillips, Walg..
PR
09/21MERCK : Building Sustainable Value for our Business and Society
PU
09/20MERCK : KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Ris..
AQ
09/20MERCK : KEYTRUDA (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Che..
AQ
09/20MERCK : Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination With..
AQ
09/20MERCK : KEYTRUDA (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in P..
AQ
09/19MERCK : KEYTRUDA« (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Ch..
BU
09/19Merck’s Keytruda« Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as..
CI
09/18MERCK : KEYTRUDA« (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Ri..
BU
09/18MERCK : KEYTRUDA« (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in ..
BU
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 46 881 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 15,7x
Yield 2021 3,60%
Capitalization 182 B 182 B -
EV / Sales 2021 4,22x
EV / Sales 2022 3,81x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 72,04 $
Average target price 93,42 $
Spread / Average Target 29,7%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-11.93%182 360
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY38.48%206 972